SLC35G1

Summary

SLC35G1 (solute carrier family 35 member G1, HGNC:26607) is a protein-coding gene on chromosome 10q23.33, encoding Solute carrier family 35 member G1 (Q2M3R5). May play a role in intracellular calcium sensing and homeostasis.

This gene encodes a transmembrane protein which is a member of the drug/metabolite transporter protein superfamily. The encoded protein may play a role in the regulation of calcium levels inside the cell.

Source: NCBI Gene 159371 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 47 total
• MANE Select transcript: NM_001134658

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26607
Approved symbol	SLC35G1
Name	solute carrier family 35 member G1
Location	10q23.33
Locus type	gene with protein product
Status	Approved
Aliases	FLJ33990, C10orf60, POST
Ensembl gene	ENSG00000176273
Ensembl biotype	protein_coding
OMIM	617167
Entrez	159371

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 6 protein_coding, 4 nonsense_mediated_decay

ENST00000371408, ENST00000427197, ENST00000483386, ENST00000494992, ENST00000603665, ENST00000605679, ENST00000899835, ENST00000899836, ENST00000899837, ENST00000957627

RefSeq mRNA: 3 — MANE Select: NM_001134658 NM_001134658, NM_001345993, NM_153226

CCDS: CCDS44459, CCDS7432

Canonical transcript exons

ENST00000427197 — 3 exons

Exon	Start	End
ENSE00001742384	93898571	93898751
ENSE00003841935	93893978	93894211
ENSE00003895817	93900752	93903824

Expression profiles

Bgee: expression breadth ubiquitous, 185 present calls, max score 97.61.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 10.2345 / max 317.2405, expressed in 1690 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
106298	9.2976	1682
106299	0.9370	530

Top tissues by expression

247 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	97.61	gold quality
jejunal mucosa	UBERON:0000399	96.27	gold quality
oocyte	CL:0000023	95.76	gold quality
duodenum	UBERON:0002114	93.52	gold quality
ileal mucosa	UBERON:0000331	86.95	gold quality
mucosa of transverse colon	UBERON:0004991	85.30	gold quality
tibialis anterior	UBERON:0001385	85.17	silver quality
cortical plate	UBERON:0005343	81.25	gold quality
rectum	UBERON:0001052	80.77	gold quality
body of pancreas	UBERON:0001150	80.23	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	79.65	gold quality
small intestine	UBERON:0002108	79.39	gold quality
transverse colon	UBERON:0001157	78.27	gold quality
jejunum	UBERON:0002115	78.15	gold quality
pigmented layer of retina	UBERON:0001782	77.68	gold quality
small intestine Peyer’s patch	UBERON:0003454	77.43	gold quality
pancreatic ductal cell	CL:0002079	77.16	silver quality
pancreas	UBERON:0001264	76.70	gold quality
intestine	UBERON:0000160	75.93	gold quality
epithelial cell of pancreas	CL:0000083	75.90	gold quality
adrenal tissue	UBERON:0018303	75.31	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	75.26	gold quality
stromal cell of endometrium	CL:0002255	75.08	gold quality
colon	UBERON:0001155	74.91	gold quality
large intestine	UBERON:0000059	74.55	gold quality
ganglionic eminence	UBERON:0004023	74.35	gold quality
upper arm skin	UBERON:0004263	73.95	gold quality
left ovary	UBERON:0002119	73.33	gold quality
smooth muscle tissue	UBERON:0001135	73.23	gold quality
right ovary	UBERON:0002118	72.98	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.34
E-MTAB-7303	no	98.30

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): E2F1

miRNA regulators (miRDB)

95 targeting SLC35G1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-96-5P	99.95	72.80	2140
HSA-MIR-1-3P	99.93	72.35	1914
HSA-MIR-206	99.93	72.50	1893
HSA-MIR-4760-3P	99.93	70.50	2385
HSA-MIR-205-3P	99.92	69.92	3165
HSA-MIR-497-5P	99.92	71.83	2674
HSA-MIR-613	99.91	71.50	1710
HSA-MIR-6809-3P	99.91	71.45	3814
HSA-MIR-3529-3P	99.90	73.55	3045
HSA-MIR-4753-3P	99.90	71.03	3786

Literature-anchored findings (GeneRIF, showing 3)

• results suggest that ubiquitinated proteins are exported from the nucleus to the cytosol in the UBIN-POST complex-dependent manner for the maintenance of nuclear protein homeostasis. (PMID:29666234)
• Discovery and Validation of Novel Genes in a Large Chinese Autism Spectrum Disorder Cohort. (PMID:37393044)
• SLC35G1 is a highly chloride-sensitive transporter responsible for the basolateral membrane transport in intestinal citrate absorption. (PMID:39508819)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	slc35g1	ENSDARG00000063268
mus_musculus	Slc35g1	ENSMUSG00000044026
rattus_norvegicus	Slc35g1	ENSRNOG00000081116
drosophila_melanogaster	CG5281	FBGN0037902

Paralogs (5): SLC35G3 (ENSG00000164729), SLC35G2 (ENSG00000168917), SLC35G5 (ENSG00000177710), SLC35G4 (ENSG00000236396), SLC35G6 (ENSG00000259224)

Protein

Protein identifiers

Solute carrier family 35 member G1 — Q2M3R5 (reviewed: Q2M3R5)

Alternative names: Partner of STIM1, Transmembrane protein 20

All UniProt accessions (3): D3DR41, Q2M3R5, S4R2Y7

UniProt curated annotations — full annotation on UniProt →

Function. May play a role in intracellular calcium sensing and homeostasis. May act as a negative regulator of plasma membrane calcium-transporting ATPases preventing calcium efflux from the cell.

Subunit / interactions. Interacts with STIM1; stimulated by depletion of intracellular calcium. Interacts with ORAI1. Interacts with the plasma membrane calcium-transporting ATPases ATP2B1 and ATP2B4. Interacts with ATP1A1, ATP2A2, KPNB1 and XPO1.

Subcellular location. Cell membrane. Endoplasmic reticulum membrane.

Tissue specificity. Ubiquitously expressed.

Similarity. Belongs to the TMEM20 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q2M3R5-1	1	yes
Q2M3R5-2	2

RefSeq proteins (3): NP_001128130, NP_001332922, NP_694958 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000620	EamA_dom	Domain
IPR037185	EmrE-like	Homologous_superfamily

Pfam: PF00892

UniProt features (16 total): transmembrane region 10, domain 2, chain 1, region of interest 1, compositionally biased region 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q2M3R5-F1	80.80	0.53

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 143 (showing top): GSE45365_NK_CELL_VS_CD11B_DC_UP, BENPORATH_ES_WITH_H3K27ME3, GOBP_MONOATOMIC_CATION_TRANSPORT, BILD_E2F3_ONCOGENIC_SIGNATURE, GOBP_REGULATION_OF_CYTOSOLIC_CALCIUM_ION_CONCENTRATION, GOBP_MONOATOMIC_ION_HOMEOSTASIS, GOBP_CALCIUM_ION_TRANSMEMBRANE_TRANSPORT, GOBP_TRANSMEMBRANE_TRANSPORT, GOBP_HOMEOSTATIC_PROCESS, GOBP_CHEMICAL_HOMEOSTASIS, GOCC_NUCLEAR_OUTER_MEMBRANE_ENDOPLASMIC_RETICULUM_MEMBRANE_NETWORK, GOCC_ORGANELLE_SUBCOMPARTMENT, GEORGES_TARGETS_OF_MIR192_AND_MIR215, chr10q23, KRIGE_RESPONSE_TO_TOSEDOSTAT_6HR_DN

GO Biological Process (2): regulation of cytosolic calcium ion concentration (GO:0051480), calcium ion export across plasma membrane (GO:1990034)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (4): endoplasmic reticulum membrane (GO:0005789), plasma membrane (GO:0005886), endoplasmic reticulum (GO:0005783), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
intracellular calcium ion homeostasis	1
calcium ion transmembrane transport	1
export across plasma membrane	1
binding	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
membrane	1
cell periphery	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

684 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SLC35G1	STIM1	Q13586	766
SLC35G1	SARAF	Q96BY9	727
SLC35G1	ORAI1	Q96D31	717
SLC35G1	SLC35E1	Q96K37	573
SLC35G1	STIMATE	Q86TL2	568
SLC35G1	SLC35E3	Q7Z769	523
SLC35G1	BIN2	Q9UBW5	509
SLC35G1	SLC35C1	Q96A29	507
SLC35G1	ITPR3	Q14573	498
SLC35G1	ITPR1	Q14643	493
SLC35G1	PLCE1	Q9P212	483
SLC35G1	SCOC	Q9UIL1	481
SLC35G1	CRACR2A	Q9BSW2	480
SLC35G1	ANKFN1	Q8N957	475
SLC35G1	STIM2	Q9P246	474

IntAct

37 interactions, top by confidence:

A	B	Type	Score
ORAI1	STIM1	psi-mi:“MI:0403”(colocalization)	0.960
SLC35G1	ATP2B1	psi-mi:“MI:0915”(physical association)	0.620
ATP2B1	SLC35G1	psi-mi:“MI:0915”(physical association)	0.620
SLC35G1	TMEM14B	psi-mi:“MI:0915”(physical association)	0.560
SLC18A1	SLC35G1	psi-mi:“MI:0915”(physical association)	0.560
SLC35G1	YIPF1	psi-mi:“MI:0915”(physical association)	0.560
SLC35G1	TMEM237	psi-mi:“MI:0915”(physical association)	0.560
EBP	SLC35G1	psi-mi:“MI:0915”(physical association)	0.560
SLC35G1	FAM210B	psi-mi:“MI:0915”(physical association)	0.560
ORAI1	SLC35G1	psi-mi:“MI:0915”(physical association)	0.560
SLC35G1	STIM1	psi-mi:“MI:0403”(colocalization)	0.540
SLC35G1	STIM1	psi-mi:“MI:0915”(physical association)	0.540
PRKCZ	IPO5	psi-mi:“MI:0914”(association)	0.530
PRKCI	POLRMT	psi-mi:“MI:0914”(association)	0.350
PRKCZ	POLRMT	psi-mi:“MI:0914”(association)	0.350
SLC35G1	SUPT5H	psi-mi:“MI:0914”(association)	0.350
SLC35G1	FAM234B	psi-mi:“MI:0914”(association)	0.350
SLC35G1	XPO1	psi-mi:“MI:0914”(association)	0.350
STIM1	XPO1	psi-mi:“MI:0914”(association)	0.350
SLC35G1	TMEM237	psi-mi:“MI:0915”(physical association)	0.000
TMEM14B	SLC35G1	psi-mi:“MI:0915”(physical association)	0.000
SLC35G1	SLC18A1	psi-mi:“MI:0915”(physical association)	0.000
YIPF1	SLC35G1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (120): SLC35G1 (Affinity Capture-MS), SLC35G1 (Two-hybrid), SLC35G1 (Two-hybrid), SLC35G1 (Two-hybrid), SLC35G1 (Two-hybrid), SLC35G1 (Two-hybrid), SLC35G1 (Two-hybrid), SLC35G1 (Affinity Capture-MS), SLC35G1 (Affinity Capture-MS), SLC35G1 (Affinity Capture-MS), SLC35G1 (Affinity Capture-RNA), RNF213 (Affinity Capture-MS), AGGF1 (Affinity Capture-MS), GLMN (Affinity Capture-MS), SCYL1 (Affinity Capture-MS)

ESM2 similar proteins: A2AKQ0, A2VE55, A5GFZ5, B8B7Q4, F4JN00, O14494, O42602, O60762, O70152, O75352, O88956, P0CK96, P60588, Q15B89, Q1JQ93, Q28HF8, Q2M3R5, Q3ZCD7, Q4L208, Q4R8V4, Q52KD1, Q5PT50, Q5PT53, Q5RDC9, Q5XF09, Q5ZJ75, Q5ZJH8, Q64232, Q6DBP3, Q6DHK8, Q6NMB6, Q6ZL17, Q762D5, Q76EJ3, Q7T0V6, Q8C811, Q8GUJ1, Q8IVW8, Q8R4D1, Q8RXL8

Diamond homologs: Q2M3R5, Q8BY79

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
FAM20C	“up-regulates activity”	SLC35G1	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

47 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	38
Likely benign	6
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

328 predictions. Top by Δscore:

Variant	Effect	Δscore
10:93894158:GCG:G	donor_gain	0.9900
10:93894157:CGCG:C	donor_loss	0.9800
10:93894160:GGT:G	donor_loss	0.9800
10:93894161:G:GG	donor_gain	0.9800
10:93894162:T:TC	donor_loss	0.9800
10:93900750:A:AG	acceptor_gain	0.9800
10:93900751:G:GG	acceptor_gain	0.9800
10:93900751:GAACT:G	acceptor_gain	0.9800
10:93894163:AG:A	donor_loss	0.9700
10:93894164:G:GC	donor_loss	0.9700
10:93894165:G:C	donor_loss	0.9700
10:93900751:GA:G	acceptor_gain	0.9600
10:93894207:GCCGG:G	donor_gain	0.9500
10:93900747:TACA:T	acceptor_loss	0.9300
10:93900748:ACAG:A	acceptor_loss	0.9300
10:93900749:CA:C	acceptor_loss	0.9300
10:93900750:A:T	acceptor_loss	0.9300
10:93900741:T:A	acceptor_loss	0.9200
10:93900751:GAAC:G	acceptor_gain	0.9200
10:93894210:GG:G	donor_gain	0.9100
10:93894211:GG:G	donor_gain	0.9100
10:93894208:CCGG:C	donor_loss	0.8800
10:93894209:CGGGT:C	donor_loss	0.8800
10:93894210:GGGT:G	donor_loss	0.8800
10:93894211:GGTG:G	donor_loss	0.8800
10:93894212:G:T	donor_loss	0.8800
10:93894213:T:TG	donor_loss	0.8800
10:93894214:GA:G	donor_loss	0.8800
10:93894215:AGTG:A	donor_loss	0.8800
10:93894216:G:C	donor_loss	0.8800

AlphaMissense

2375 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:93898693:A:C	S101R	0.995
10:93898695:T:A	S101R	0.995
10:93898695:T:G	S101R	0.995
10:93900885:A:C	S165R	0.995
10:93900887:C:A	S165R	0.995
10:93900887:C:G	S165R	0.995
10:93898703:G:C	R104P	0.994
10:93901305:G:C	A305P	0.994
10:93900801:G:A	G137R	0.993
10:93900801:G:C	G137R	0.993
10:93901306:C:A	A305E	0.993
10:93901443:A:C	S351R	0.993
10:93901445:T:A	S351R	0.993
10:93901445:T:G	S351R	0.993
10:93901431:T:C	C347R	0.992
10:93900978:G:A	G196R	0.990
10:93900978:G:C	G196R	0.990
10:93900979:G:A	G196E	0.990
10:93901176:G:C	G262R	0.989
10:93901423:G:A	G344D	0.989
10:93900802:G:A	G137E	0.988
10:93901422:G:C	G344R	0.988
10:93900810:G:C	G140R	0.986
10:93900867:G:C	A159P	0.986
10:93900913:C:A	A174D	0.986
10:93901099:C:A	A236E	0.985
10:93901177:G:A	G262D	0.984
10:93901266:G:A	G292R	0.984
10:93901266:G:C	G292R	0.984
10:93901335:G:C	A315P	0.982

dbSNP variants (sampled 300 via entrez): RS1000202563 (10:93902045 C>A), RS1000332610 (10:93904872 G>A), RS1000470021 (10:93905094 T>C), RS1000666223 (10:93903371 G>C), RS1000801900 (10:93903681 A>G), RS1001082231 (10:93898875 C>A,T), RS1001203081 (10:93893095 C>T), RS1001245984 (10:93898382 A>T), RS1001285692 (10:93892786 T>A), RS1001669958 (10:93898486 C>G,T), RS1001691649 (10:93905779 G>A), RS1001930426 (10:93904089 A>G), RS1002023957 (10:93904384 C>T), RS1002139441 (10:93897410 A>G), RS1002205817 (10:93898947 A>G)

Disease associations

OMIM: gene MIM:617167 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST003465_25	Cannabis dependence symptom count	1.000000e-09
GCST009174_2	Response to (pegylated) interferon in chronic hepatitis B	1.000000e-06

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0008457	cannabis dependence measurement
EFO:0007859	response to interferon

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: transporter — SLC35 family of nucleotide sugar transporters

CTD chemical–gene interactions

35 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, affects expression	4
trichostatin A	affects cotreatment, decreases expression	3
sodium arsenite	decreases expression, increases expression	2
Nickel	decreases expression	2
Phenylmercuric Acetate	decreases expression, affects cotreatment	2
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
perfluorooctane sulfonic acid	decreases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
NSC 689534	affects binding, decreases expression	1
(+)-JQ1 compound	decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	decreases expression	1
Bortezomib	decreases expression	1
Sunitinib	decreases expression	1
Arsenic Trioxide	decreases expression	1
Acetaminophen	decreases expression	1
Copper	affects binding, decreases expression	1
Demecolcine	decreases expression	1
Estradiol	increases expression	1
Ethyl Methanesulfonate	increases expression	1
Formaldehyde	decreases expression	1
Methyl Methanesulfonate	decreases expression	1
Oxygen	decreases expression	1
Smoke	decreases expression	1
T-2 Toxin	decreases expression	1
Tobacco Smoke Pollution	increases expression	1

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D4MP	HCT116-SLC35G1-KO-c3	Cancer cell line	Male
CVCL_D4MQ	HCT116-SLC35G1-KO-c4	Cancer cell line	Male
CVCL_TN30	HAP1 SLC35G1 (-)	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer